ELOX Eloxx Pharmaceuticals
- 0.880
- -0.081-8.44%
Eloxx Pharmaceuticals News
Alport Syndrome Pipeline Insight 2024, Featuring Eloxx Pharmaceuticals, Chinook Therapeutic, River 3 Renal Corp., Travere Therapeutics and Reata Pharmaceuticals
Eloxx Pharmaceuticals CEO Stock Option Repricing Initiative
Almirall and Eloxx Pharmaceuticals Enter Into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases
Almirall obtains exclusive global rights to develop and commercialize ZKN-013 for the treatment of rare dermatological and other diseases associated with nonsense mutations ZKN-013 is a phase I read
Almirall Signs License Deal With Eloxx Pharmaceuticals for Skin Diseases Treatment
Almirall (ALM.MC) signed an exclusive license agreement with Eloxx Pharmaceuticals for the latter's skin disease treatment candidate ZKN-013. The Spanish pharmaceutical company will secure the rights
Eloxx Pharmaceuticals 3Q Loss/Shr $1.31 >ELOX
Eloxx Pharmaceuticals 3Q Loss/Shr $1.31 >ELOX
Press Release: Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update
Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update Kidney morphology improved in all three patients with protein re-expression consistent wi
Oppenheimer Adjusts Eloxx Pharmaceuticals Price Target to $30 From $60, Maintains Outperform Rating
Oppenheimer Adjusts Eloxx Pharmaceuticals Price Target to $30 From $60, Maintains Outperform Rating
12 Health Care Stocks Moving In Friday's After-Market Session
GainersBellerophon Therapeutics (NASDAQ:BLPH) stock moved upwards by 17.1% to $0.12 during Friday's after-market session. Trading volume for this security closed at 2.1 million, accounting for 1394.7%
Eloxx Pharmaceuticals Reports Positive Biopsy Results, ELX-02 Shows Promise in Alport Syndrome Treatment
Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today reported results from an assessment of patient biopsies by NIPOKA GmbH (Nipoka)
Eloxx Pharmaceuticals Reports Additional Confirmation That All Nonsense Mutation Alport Syndrome Patients Treated With ELX-02 in Phase 2 Study Had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria
Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) today reported results from an assessment of patient biopsies by NIPOKA GmbH (Nipoka). They have developed a highly accurate method for the quantification of podocyte foot process morphology.
Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
WATERTOWN, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it has entered into a
Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated With ELX-02 in Phase 2 Clinical Study for Alport Syndrome
Highly regarded renal pathologist and transmission electron microscopy (TEM) expert independently confirms previously reported qualitative assessment by Mayo Clinic of TEM biopsy scans All three patients treated with
MULN, STIX and WE Among Mid-day Movers
Oppenheimer Raises Eloxx Pharmaceuticals Price Target to $60 From $55, Maintains Outperform Rating
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: Price: 4.85, Change: +0.21,
Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013
Investigational New Drug (IND) application submitted to U.S. Food and Drug Administration (FDA) for ELX-02 for the treatment of Alport syndrome with nonsense mutations Rebound in average UPCR 3-months post treatment
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersNovo Integrated Sciences (NASDAQ:NVOS) stock moved upwards by 23.5% to $0.14 during Tuesday's after-market session. This security traded at a volume of 29.7 million shares come close, making up
Eloxx Pharmaceuticals Q2 EPS $(1.96) Misses $(1.54) Estimate
Eloxx Pharmaceuticals (NASDAQ:ELOX) reported quarterly losses of $(1.96) per share which missed the analyst consensus estimate of $(1.54) by 27.27 percent. This is a 1533.33 percent decrease over loss
Eloxx Pharmaceuticals: Current Cash Position Sufficient to Fund Operations Into 4Q >ELOX
Eloxx Pharmaceuticals: Current Cash Position Sufficient to Fund Operations Into 4Q >ELOX
Press Release: Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update
Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update Announced today that all 3 patients (100% response rate) treated with ELX-02 showed an i
Eloxx Pharmaceuticals 2Q Loss/Shr $1.96 >ELOX
Eloxx Pharmaceuticals 2Q Loss/Shr $1.96 >ELOX
Analysis
Price Target
No Data
